The Bottom Line GLP-1s arent the villain
Patients should expect continued follow-up, medication monitoring, and conversations about nutrition, activity, side effects, and progress
PRESS RELEASE PHILADELPHIA, July 30, 2024 A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimers Association International Conference (AAIC ) 2024, in Philadelphia and online
Early studies also suggest that Thymalin, along with other extracts from the thymus and pineal gland, may contribute to extending lifespan
Download the full article as PDF here Salcaprozate-based ionic liquids for GLP-1 gastric delivery or read it here Materials The API and SNAC were supplied by Novo Nordisk
Declarations Acknowledgement The authors acknowledge DST-FIST for sponsoring the Department of Biotechnology, Central University of Tamil Nadu